Flexible, Science-Based Solutions to Meet the Needs of Your Patients

Customizable Solutions for Individualized Outcomes

The Similac® Liqui-Mix® System and Liquid Protein Fortifier can be used to customize calories and protein in an all-liquid solution.

SIMILAC LIQUI-MIX SYSTEM 

  • All-liquid solution eliminates the need for most powder mixing 

  • Easy to customize feedings, including 20, 24, 26, 27, and 28 cal/fl oz

  • Easy to customize protein levels with Liquid Protein Fortifier

SIMILAC® NEOSURE® 

Nutrient-enriched* preterm post-discharge formula shown to improve overall growth1

CLINICALLY PROVEN SIMILAC® HUMAN MILK FORTIFIER HYDROLYZED PROTEIN CONCENTRATED LIQUID (HMF HP CL)

THE FIRST HUMAN MILK FORTIFIER WITH EXTENSIVELY HYDROLYZED PROTEIN

Supported by 5 clinical studies, our human milk fortifier has been shown to deliver excellent outcomes.2-6 

IMPROVED TOLERANCE3,4,6

IMPROVED BLOOD UREA NITROGEN (BUN) LEVELS2,4

IMPROVED WEIGHT GAIN2-4,6,‡

FEWER ADVERSE EVENTS AND/OR LESS ACIDOSIS3-6

SAFE HANDLING AND USE

  • Packaged in single-use, ready-to-use packets for precise dosing and nutrient delivery 

  • Liquid form reduces the risk for environmental contamination 

  • Packets allow for aseptic handling when used as directed

  • Developed with a focus on safe handling for NICU use 

KEY CLINICAL STUDY SHOWS IMPORTANT GAINS IN GROWTH7

Similac® offers the FIRST nonacidified human milk fortifier that has extensively hydrolyzed protein.

  • Similac HMF HP CL infants gained 0.5 lb more weight at study day 29, and both groups increased in weight and length over time 

  • Similac HMF HP CL delivers 4.3g§ of protein (g/kg/day)

Evaluable patients (n = 75).

Hash marks indicate standard error. 

ǁ Weight, g. Repeated Measures Analysis main effect, P = 0.036; post-hoc per timepoint analysis: SDAY 29, P = 0.024. Length, cm. Repeated Measures Analysis main effect, P = 0.029; post-hoc per timepoint analysis: SDAY 22, P = 0.006, SDAY 29, P = 0.037.

¶ These infants strictly adhered to study protocol and received ≥95% of their total intake from human milk with their assigned study fortifier. 

FEATURES OF SIMILAC HMF HP CL

  • Extensively hydrolyzed protein source to help promote easy digestion

  • Has OptiGRO® for brain and eye development 

  • Low iron level provides flexibility to add iron as needed

KEY CLINICAL STUDY SHOWS TOLERANCE7

Well tolerated 

  • Only 1 in 66 (1.5%) NICU patients in the Similac HMF HP CL group discontinued due to feeding intolerance 

  • No incidence of metabolic acidosis with infants fed Similac HMF HP CL or control  
     

Improved protein status 

  • Recent studies have identified BUN levels of >9 mg/dL as an indicator of protein sufficiency in preterm infants8-10 

  • BUN levels remained above 9 mg/dL in preterm infants receiving Similac HMF HP CL

     

Mean BUN levels

EFFECTS OF AN ACIDIC pH ON HUMAN MILK

In vitro study of human milk acidified with citric acid to a pH of 4.511

Similac HMF retains the pH of human milk to near neutral range, which should preserve the unique benefits of human milk.

* Increased protein, vitamins, and minerals compared to term infant formula.
† Launched in 2014. First nonacidified human milk fortifier that is hydrolyzed.
‡ In the Schanler study, weight gain was improved SDAY1-SDAY15.
§ Composition of human milk-based feedings at 120 kcal/kg and 24 Cal/fl oz. 

References: 1. Carver JD, et al. Pediatrics. 2001;107(4):683-689. 2. Kim J, et al. J Pediatr Gastroenterol Nutr. 2015;61(6):665-671. 3. Kumar N, et al. Am J Perinatol. 2017;34(14):1411-1416. 4. Schanler RJ, et al. J Pediatr. 2018;202:31-37.e2. 5. Lainwala S, et al. J Neonatal Perinatal Med. 2017;10(4):393-401. 6. Clark B, et al. J Acad Nutr Diet. 2017;117(9 suppl 1):A11. 7. Kim JH, et al. J Pediatr Gastroenterol Nutr. 2015;61(6):605-671. 8. Arslanoglu S, et al. J Perinatol. 2006;26:614-621. 9. Alan S, et al. Early Hum Dev. 2013;89:1017-1023. 10. Ergenekon E, et al. Turk J Pediatr. 2013;55:365-370. 11. Erickson T, et al. J Perinatol. 2013;33:371-373.

 

Error

Something went wrong, please close this window and try again.

Confirmation

This article has been removed from My Resources.

Please click "Accept Sale/Sharing and Targeted Advertising" to enable full site functionality.

At this time, we are experiencing problems with broken links on our site. As an interim solution, for full site functionality you must enable functional and advertising cookies. If you continue to opt-out of these cookies, some content on our site may not be viewable.

We use functional cookies to analyze your use of the site, improve performance and provide a better customer experience. We use advertising cookies to allow us, through certain data assigned and obtained from the user's device, to store or share with third parties information related to user's browsing activity in our website, in order to create an advertising profile and place relevant advertising in our website or those third parties websites. For more information about how Abbott uses cookies please see our Cookie Policy and Privacy Policy.

In order to accept functional and advertising cookies, please click "Enable Cookies" and then click "Accept Sale/Sharing and Targeted Advertising" to view the full site.

Collapse
Learn more about cookies